---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-011514"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:41:24.535550+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics reports positive Phase 3 results for SAB-185 in high-risk COVID-19 patients

## Summary
- 66% of SAB-185 patients reached sustained symptom resolution by Day 28 vs 50% for REGEN-COV (p=0.010).
- Median time to symptom resolution was 7 days shorter for SAB-185 vs REGEN-COV (p=0.010).
- Primary endpoint (hospitalization/death) inconclusive due to low events after Omicron emergence.
- Grade 3+ adverse event rates similar between SAB-185 and REGEN-COV arms.
- SAB-176 for influenza granted Fast Track and Breakthrough Therapy designations from FDA.

## SEC filing metadata
- accession: 0001437749-23-011514
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000143774923011514/0001437749-23-011514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000143774923011514/sabs20230427_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-011514
- JSON: https://secwatch.observer/filing/0001437749-23-011514.json
- Plain text: https://secwatch.observer/filing/0001437749-23-011514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.